Compare CFG & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFG | NTRA |
|---|---|---|
| Founded | 1828 | 2003 |
| Country | United States | United States |
| Employees | 17398 | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4B | 28.0B |
| IPO Year | N/A | 2015 |
| Metric | CFG | NTRA |
|---|---|---|
| Price | $63.67 | $211.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 15 |
| Target Price | $70.17 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 4.2M | 1.2M |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.86% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,939,000.00 |
| Revenue This Year | $20.17 | $18.08 |
| Revenue Next Year | $8.30 | $19.65 |
| P/E Ratio | $16.85 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.93 | $131.81 |
| 52 Week High | $68.79 | $256.36 |
| Indicator | CFG | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.89 | 55.17 |
| Support Level | $58.09 | $185.17 |
| Resistance Level | $66.37 | $220.33 |
| Average True Range (ATR) | 1.46 | 8.98 |
| MACD | -0.24 | 0.46 |
| Stochastic Oscillator | 7.12 | 71.71 |
Citizens Financial Group Inc is a bank holding company headquartered in Providence, Rhode Island. Through its subsidiaries, it offers various retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations, and institutions. The group's reportable business segments are: Consumer Banking and Commercial Banking. The majority of its revenue is generated from the Consumer Banking segment, which serves consumer customers and small businesses, offering traditional banking products and services, including deposits, mortgage and home equity lending, credit cards, small business loans, education loans, point-of-sale finance loans, and wealth management solutions, among others, through a network of branches and ATMs.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.